Sun Pharmaceuticals Industries Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Mid Cap

Sun Pharmaceuticals Industries announced that the U.S. Food and Drug Administration (FDA) approved LEQSELVI™ (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata.

“LEQSELVI offers a new and effective solution that will significantly enhance options for long-suffering patients battling severe alopecia areata and their physicians,” said Abhay Gandhi, CEO, North America Business, Sun Pharma. “Our fast-growing dermatology business is excited to add this novel treatment to its portfolio.

Powered by Capital Market - Live News

Sun Pharmaceuticals Industries Ltd gained for a fifth straight session today. The stock is quoting at Rs 1697.15, up 1.88% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 1.28% on the day, quoting at 24718.65. The Sensex is at 80971.98, up 1.16%. Sun Pharmaceuticals Industries Ltd has gained around 11.93% in last one month.

Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has gained around 10% in last one month and is currently quoting at 21105.5, up 1.71% on the day. The volume in the stock stood at 25.62 lakh shares today, compared to the daily average of 19.27 lakh shares in last one month.

The benchmark August futures contract for the stock is quoting at Rs 1705.5, up 1.91% on the day. Sun Pharmaceuticals Industries Ltd is up 49.54% in last one year as compared to a 25.73% jump in NIFTY and a 43.88% jump in the Nifty Pharma index.

The PE of the stock is 130.91 based on TTM earnings ending March 24.

Powered by Capital Market - Live News

The domestic equity indices traded with robust gains in the mid-morning trade. The Nifty scaled above the 24,600 level. IT shares gained after declining in the past trading session.

At 11:30 IST, the barometer index, the S&P BSE Sensex, was up 646.71 points or 0.80% to 80,678.94. The Nifty 50 index rallied 235.35 points or 0.95% to 24,638.95.

The broader market outperformed the headline indices. The S&P BSE Mid-Cap index gained 1.70% and the S&P BSE Small-Cap index added 1.11%.

The market breadth was strong. On the BSE, 2,701 shares rose and 1,040 shares fell. A total of 115 shares were unchanged.

Buzzing Index:

The Nifty IT index added 1.96% to 40,839.70. The index shed 0.03% in the past trading sessions.

Mphasis (up 6.77%), LTIMindtree (up 2.61%), Infosys (up 2.53%), Wipro (up 2.25%), HCL Technologies (up 2.11%), Persistent Systems (up 2.01%), Tata Consultancy Services (up 1.37%), Coforge (up 0.78%), L&T Technology Services (up 0.1%) advanced.

Stocks in Spotlight:

Sun Pharmaceutical Industries gained 2.58% after the pharma major said that it has received approval from the U.S. Food and Drug Administration (US FDA) for LEQSELVI (deuruxolitinib), an oral JAK Inhibitor for the treatment of severe alopecia areata.

VST Industries added 2.79% after the company said that its board has recommended issue of bonus shares in the ratio of 10:1, i.e. ten new bonus equity shares of Rs 10 each for every one existing fully paid equity share of Rs 10 each.

Tech Mahindra shed 0.29%. The IT major's consolidated net profit jumped 28.82% to Rs 851.5 crore on 1.04% rise in revenue from operations to Rs 13,005.5 crore in Q1 FY25 over in Q1 FY24.

Global Markets:

Asian stocks traded mixed on Friday as investors digested Tokyo's latest inflation data and awaited key U.S. economic figures. Japan’s headline inflation eased slightly to 2.2% in July, while core inflation held steady at 2.2%.

The market's focus now shifts to the U.S., where the release of the personal consumption expenditure (PCE) index – the Federal Reserve's preferred inflation gauge – is expected to influence interest rate expectations.

Meanwhile, U.S. stocks experienced a rotation away from technology shares on Thursday, with the Nasdaq Composite and S&P 500 declining. The Dow Jones Industrial Average bucked the trend with a modest gain. This shift is a common occurrence during bull markets as market leadership evolves.

Powered by Capital Market - Live News

Alopecia areata is a common autoimmune disease in which hair loss is thought to occur due to the collapse of immune privilege, leading to the immune system targeting the hair follicles and causing sudden hair loss on the scalp, face and sometimes other areas of the body.

Alopecia areata affects around 700,000 people in the United States, and 300,000 have severe alopecia areata. Alopecia often leads patients to self-treat before seeking professional help, driven by dissatisfaction with the slow progress of existing treatments.

As a JAK inhibitor, LEQSELVI interrupts the pathways thought to contribute to hair loss in severe alopecia areata.

Abhay Gandhi, CEO, North America Business, Sun Pharma, said: “LEQSELVI offers a new and effective solution that will significantly enhance options for long-suffering patients battling severe alopecia areata and their physicians. Our fast-growing dermatology business is excited to add this novel treatment to its portfolio.”

Sun Pharmaceuticals Industries is a leading global pharmaceutical company with specialty and generic presence and India's top pharma company.

The pharma major’s consolidated net profit jumped 33.77% to Rs 2,654.58 crore on 10.14% growth in revenue from operations to Rs to Rs 11,813.33 crore in Q4 FY24 over Q4 FY23.

The scrip rose 0.47% to currently trade at Rs 1672.95 on the BSE.

Powered by Capital Market - Live News